Lisata Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• Auto-CD34+ cells · Regenerative Medicine / Cardiovascular
  Auto-CD34+ cells are autologous CD34+ hematopoietic stem cells mobilized and collected from a patient's own bone marrow or peripheral blood, then reinfused to promote tissue regeneration and repair.

Phase 2 pipeline

• CLBS03 High Dose · Cardiovascular
  CLBS03 High Dose is a cell therapy that aims to repair or replace damaged heart tissue.
• CLBS03 Low Dose
• CLBS12 · Cardiovascular
  CLBS12 is a cell therapy product that aims to repair or replace damaged heart tissue.
• NBS10

Phase 1 pipeline

• CLBS201

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Lisata Therapeutics, Inc. portfolio CI brief
• Lisata Therapeutics, Inc. pipeline updates RSS